sur CureVac (NASDAQ:CVAC)
CureVac Reports Q3 and Nine-Month Financial Results for 2025
CureVac disclosed their third-quarter and nine-month financial outcomes for 2025 alongside business updates. The German Federal Cartel Office approved the planned merger with BioNTech, forecasting closure later in the year. BioNTech's exchange offer for CureVac shares began on October 21, 2025, ending December 3. Litigation with Pfizer/BioNTech over mRNA COVID-19 vaccines halted pending offer completion.
The European Medicines Agency cleared CureVac's CTA for the CVHNLC cancer candidate, and CVGBM Phase 1 proceeds as planned. CureVac's cash reserves stood at €416.1 million by September 30, 2025, continuing an expected cash runway through 2028.
Revenue fell significantly, namely due to the absence of a €480.4 million one-time GSK license agreement in 2024, while operating profit benefitted from a positive one-time U.S. Settlement Agreement effect. Net profit noted a decline, partly due to increased legal expenses related to the BioNTech merger.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CureVac